A Phase II Study to Assess the Activity and Safety of TH-302 in Combination With Sunitinib in Treatment-naïve Patients With Well- and Moderately-differentiated Metastatic Pancreatic Neuroendocrine Tumours (pNET)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 14 Jun 2018
At a glance
- Drugs Evofosfamide (Primary) ; Sunitinib (Primary)
- Indications Neuroendocrine tumours; Pancreatic cancer
- Focus Therapeutic Use
- Acronyms SUNINET
- 08 Jun 2018 Status changed from recruiting to active, no longer recruiting.
- 02 Aug 2017 According to Molecular Templates media release, Threshold Pharmaceuticals merged with Molecular Templates and the combined company is named as Molecular Templates.
- 10 Mar 2017 Planned End Date changed from 1 Apr 2018 to 1 Jun 2019.